期刊
CARDIO-ONCOLOGY
卷 5, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s40959-019-0054-5
关键词
Cardiotoxicity; Cardio-oncology; Pediatrics; Beta-blockers; ACE inhibitors; Anthracyclines; Cancer
资金
- National Institutes of Health [HL072705, HL078522, HL053392, CA127642, CA068484, HD052104, AI50274, HD052102, HL087708, HL079233, HL004537, HL087000, HL007188, HL094100, HL095127, HD80002, HD028820]
- Pfizer
- Roche Diagnostics
- Children's Cardiomyopathy Foundation
- Sofia's Hope, Inc.
- Kyle John Rymiszewski Foundation
- Children's Hospital of Michigan Foundation
- Scott Howard Fund
- Michael Garil Fund
Cancer diagnostics and therapies have improved steadily over the last few decades, markedly increasing life expectancy for patients at all ages. However, conventional and newer anti-neoplastic therapies can cause short- and long-term cardiotoxicity. The clinical implications of this cardiotoxicity become more important with the increasing use of cardiotoxic drugs. The implications are especially serious among patients predisposed to adverse cardiac effects, such as youth, the elderly, those with cardiovascular comorbidities, and those receiving additional chemotherapies or thoracic radiation. However, the optimal strategy for preventing and managing chemotherapy-induced cardiotoxicity remains unknown. The routine use of neurohormonal antagonists for cardioprotection is not currently justified, given the marginal benefits and associated adverse events, particularly with long-term use. The only United States Food and Drug Administration and European Medicines Agency approved treatment for preventing anthracycline-related cardiomyopathy is dexrazoxane. We advocate administering dexrazoxane during cancer treatment to limit the cardiotoxic effects of anthracycline chemotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据